Rheumatoid arthritis is a destructive joint disease that is caused by inflammation of the synovium, which is the tissue that lines the joints. The damage and pain can spread to other tissues around the joints, including cartilage, bones, tendons and ligaments, leading to deformity. Targeting inflammation can help prevent further deterioration and facilitate the joint tissue repair process which is crucial to break the chain of discomfort.
In this clinical trial, rheumatoid arthritis patients with knee pain were orally administered 100 mg Boswellin® Super or placebo daily for 8 weeks. Compared to baseline (week 0), patients administered with Boswellin® Super showed significant improvements in knee pain after 8 weeks, as evaluated using Visual Analog Scale (VAS), Japanese Knee Osteoarthritis Measure (JKOM), Western Ontario and McMaster Universities Arthritis Index (WOMAC). Higher VAS, JKOM and WOMAC scores indicate greater pain, stiffness and physical disabilities. Compared to placebo group, patients in Boswellin® Super group also showed lower serum hyaluronic acid levels. Hyaluronic acid is usually higher in patients with early rheumatoid arthritis. These findings suggest the beneficial effect of Boswellin® Super on patients with rheumatoid arthritis.